This paper discusses the factors, other than stoppage of the drug, which influence dechallenge. These include: time to improvement and/or time to resolution, irreversibility or partial irreversibility, tolerance or desensitization, confounding treatment of the adverse event, natural limitations, replacement therapy, reasonable time to offset, delayed or latent adverse drug reaction (ADR), dechallenge of two or more drugs simultaneously, double dechallenge, placebo dechallenge, drug withdrawal or rebound effect, stop or reduce the dose, and drug-drug interaction. Much remains to be learned about the responses to dechallenge.
PerezVSchaffnerFPopperH.Hepatotoxicity caused by drugs. In PopperHSchaffnerF (eds). Progress in Liver Disease.New York, London: Grione and Stratton; 1972, 608.
2.
SherlockS.Hepatotoxicity caused by drugs. Rat Drug Therapy.1988;22(7):5.
3.
StephensMDB.The diagnosis of adverse events associated with drug treatment. Adv Drug React Ac Pois Rev.1987;1:1–35.
4.
IsaacsAJMacarthurJBTaylorDH.Jaundice in relation to chlorpromazine. Br Med J.1955;ii: 1122.
5.
MacbrideWG.Thalidomide and congenital abnormalities. Lancet.1961: Dec. 16:1358.
6.
HerbstALUlfelderHPoskanzerDC.Association of maternal stilboestrol therapy with tumour appearance in young women. New Engl J Med.1971;284:878.
7.
LetemendiaFJJHarrisAD.The influence of side effects on the reporting of symptoms. Psychopharm.1959;1:39–47.
8.
withdrawalBeta-blockadeLancet.1975; Sept. 27:2.
9.
LagierGVincensMCastotA.Imputabilité en pharmacovigilance. Principes de la methode appréciative ponderée (MAP) et principales erreurs à éviter. Thérapie.1983;38:303–318.
10.
LaneDA.A probabilist's view of causality assessment. Drug Inf J.1984;18:323–330.
